MindLab, LLC Information

MindLab is a biopharmaceutical company developing next-generation pain therapeutics to deliver life-changing pain relief while improving the risk–benefit profile associated with today’s treatment options. Our mission is simple: ensure that no one suffers from pain without adequate, humane treatment. Our lead program, MLB-001, is a morphine-class analgesic in development for acute and severe acute pain. MLB-001 is designed to achieve morphine-level efficacy with a more controlled clinical profile—targeting real-world challenges in pain care such as durability of relief, dose requirements, tolerability, and the potential to reduce reward-driven drug liking that can contribute to misuse. MindLab has generated encouraging preclinical proof-of-concept results supporting prolonged analgesic activity versus morphine in acute pain models, and we are advancing a regulator-ready clinical strategy to evaluate safety, pharmacokinetics, and abuse liability. To learn more, visit mindlabpharma.com. MindLab is supported by an experienced team and a growing global intellectual property portfolio, including coverage in the United States, Europe, Japan, and China.